Advise you to hold on or to buy more. Looking at the charts for PCYC and GILD these issues have dropped below the 50 MA but, for very shot periods. Next week INFI can return to the 20's and above this issue's chart line. The news at the CC was upbeat, except for the extra $20M in costs for the future trials in the next year. But, as Adelene said that global registrations are now in order for the next set of trials and, "Both of these potential registration paths are based on very encouraging data from our ongoing Phase I study of IPI-145 in patients with advanced hematologic malignancies. These data give us confidence that IPI-145 has the potential to be the best-in-class PI3 kinase inhibitor in this indications". These are in-the-know statements. So, make of them for you own use.
In a tough market day the SP has held at $18.75. A good amount of accumulation has occured at this level. Accumulation occurs for so long and then the SP rises. The price has firmed today with Monday and next week being days for accumulation and at higher prices.